A new paper reports that dual immune checkpoint blockade in non-small cell lung cancer (NSCLC) shows long-term survival gains. The paper may be related to the CheckMate 743 study, but its specific focus is unclear. The topic of immune oncology (IO) is also being discussed in the context of other cancers and treatments, including hepatocellular carcinoma (HCC) and combinations with radiation therapy (RT) and targeted therapy.